ClinicalTrials.gg
RecruitingNCT07401121KOANEWAUpdated Feb 10, 2026

Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis

A Phase 1 interventional study of AAV9 Gene therapy in ALS (Amyotrophic Lateral Sclerosis), sponsored by Celosia Therapeutics Pty Ltd. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Celosia Therapeutics Pty Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia — 8 open to participants now, 13 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Australia.

Planned enrollment
36th of 44
15 · median 63
Started
2026
with 2 others
Phase 1
5 of 44
2 open now
Primary completion
2027-12
later than 10 of 12 live
Registered
42nd of 44
by date

Among the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, this one is the 36th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 10 of the 12 other live ones, and was the 42nd registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

8 of the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, or all of them as a file.
02

Study summary

This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.

Read the detailed description

CTx1000 is an investigational gene therapy that encodes a degron for targeted degradation of TDP-43 following a single dose intra cisterna magna (ICM) delivery in participants diagnosed with Amyotrophic Lateral Sclerosis (ALS).

03

Conditions studied

  • ALS (Amyotrophic Lateral Sclerosis)

Keywords

  • CTx1000
  • gene therapy
  • motor neuron disease
  • genetic medicine
  • Lou Gehrig disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ALS in accordance with the revised El Escorial criteria and TRICALS risk score
  • An overall disease duration of ≤ 2 years after the participant's first symptoms
  • No or low circulating anti-AAV9 antibodies (titre ≤ 1:50
  • Stable dosing with a standard of care ALS medication (eg, riluzole and edaravone) and other prescription medications for 30 days prior to Screening
  • Not pregnant or breastfeeding, or willing to cease breastfeeding
  • All participants must use a barrier method of

Exclusion criteria

Exclusion Criteria:

  • Any participants with genetic forms of ALS, including C9ORF72 repeat carriers, except for TARDBP gene variants, as confirmed by previous clinical history genetic testing
  • Any history of myocardial infarction or stroke within 6 months prior to Screening, or uncontrolled diabetes ( > 9%)
  • Positive test for cytomegalovirus, antibody (HCV), surface antigen (HBsAg), (HIV) antibody.
  • Inadequate organ function
  • Any participant with a current open tracheostomy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Active drug-CTx1000

    All participants will receive only one dose of the study drug

    Drug: AAV9 Gene therapy

Interventions

  • DrugAAV9 Gene therapy

    Single dose gene therapy

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of CTx1000 in ALS diagnosed participants

    Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESIs)

    Time frame: 52 weeks

Secondary outcomes

  1. To evaluate the long-term safety and tolerability of CTx1000 in ALS diagnosed participants

    Incidence of Treatment Emergent Adverse Events (TEAEs), Severe Adverse Events (SAEs) and Adverse Events of Special Interests (AESIs)

    Time frame: 3 years

  2. To evaluate the long-term pharmacodynamics and immunogenicity of CTx1000 in ALS diagnosed participants

    Changes in pre-dose biomarkers (Neurofilament light) in cerebrospinal fluid and anti-drug antibody (ADA)

    Time frame: 3 years

  3. To evaluate the long-term efficacy of CTx1000 in ALS diagnosed participants

    Changes (reduction) from pre-dose Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R)

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 40 industry-sponsored phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 23 months is close to that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Feb 10, 2026
StartActual
Jan 12, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2030
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07401121
Lead sponsor
Celosia Therapeutics Pty Ltd
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Jan 12, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Feb 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion